Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer

BMC Gastroenterology

Nong-Hua Lv²  Yan Hong¹  Xiao-Hua Liu¹  Qing Li¹  Kun-He Zhang²  Chao-Zhu He¹ 

[1] Nursing College of Nanchang University, Nanchang, Jiangxi, 330006, China;Department of Gastroenterology, The First Affiliated Hospital of Nanchang University; Jiangxi Institute of Gastroenterology & Hepatology, Nanchang, Jiangxi, 330006, China

关键词: CA19-9;    CA125;    AFP;    CEA;    Tumor markers;    Gastric cancer;   

Others  :  857975
DOI  :  10.1186/1471-230X-13-87

 received in 2012-12-29, accepted in 2013-05-07,  发布年份 2013

【 摘 要 】

Background

The detection of serum tumor marker becomes a common method for screening tumors. However, this method has not been widely used for routine gastric cancer screening. In this study we aimed to determine whether the combined use of tumor markers may increase the sensitivity for the diagnosis of gastric cancer.

Methods

Serum AFP, CEA, CA125 and CA19-9 levels were measured in 149 patients with gastric cancer, 111 patients with benign gastric diseases and 124 healthy people, who visited the First Affiliated Hospital of Nanchang University from May 2011 to May 2012. Statistical analysis including receiver operating characteristic (ROC) curve, the area under the curve (AUC), and logistic regression analysis was performed to evaluate the diagnostic value of these markers on gastric cancer.

Results

Serum levels of CEA, CA125, and CA19-9 in gastric cancer group were higher than that in the benign gastric disease group and the healthy control group (P <0.005). The sensitivity of AFP, CEA, CA125 and CA19-9 in the diagnosis of gastric cancer was 4.7-20.8% individually, and increased to 40.3% in combination. By using optimal cut-off value, the sensitivity of CEA, CA125, and CA19-9 for the diagnosis of gastric cancer was improved. Especially, the sensitivity of CEA increased to 58.4% and the sensitivity of combined use of four markers increased to 69.1%. The age and gender had no effects on the diagnostic value of these markers.

Conclusions

The determination and application of optimal cut-off values based on ROC curve and logistic regression analysis could improve the diagnosis of gastric cancer based on common tumor markers.

【 授权许可】

   
2013 He et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Jackson C, Cunningham D, Oliveira J: Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20(Suppl 4):34-36.
• [2]Haglund C, Kuusela P, Roberts P, Jalanko H: Tumour marker CA 125 in patients with digestive tract malignancies. Scand J Clin Lab Invest 1991, 51(3):265-270.
• [3]Ychou M, Duffour J, Kramar A: Clinical significance and prognostic Value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers 2000, 16(3–4):105-110.
• [4]Li Y, Yang Y, Lu M: Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. Hepatogastroenterology 2011, 58(112):2166-2170.
• [5]Bornschein J, Selgrad M, Wex T, Kuester D, Malfertheiner P: Serological assessment of gastric mucosal atrophy in gastric cancer. BMC Gastroenterol 2012, 12:10. BioMed Central Full Text
• [6]Zur B, Holdenrieder S, Walgenbach-Brünagel G, Albers E, Stoffel-Wagner B: Method comparison for determination of the tumor markers AFP, CEA, PSA and free PSA between Immulite 2000 XPI and Dimension Vista 1500. Clin Lab 2012, 58(1–2):97-105.
• [7]Cui W, Lu X, Zheng S, Ma Y, Liu X, Zhang W: The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor. Clin Lab 2012, 58(5–6):419-426.
• [8]Lai IR, Lee WJ, Huang MT: Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterol 2002, 49:1157-1160.
• [9]Chen XZ, Zhang WK, Kun Y: Correlation between serum CA724 and gastric cancer: multiple analyses based on Chinese population. Mol Biol Rep 2012, 39:9031-9039.
• [10]Duraker N, Celik AN: The prognostic significance of preoperative serum CA 19–9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol 2001, 76(4):266-271.
• [11]Fan B, Xiong B: Investigation of serum tumor markers in the diagnosis of gastric cancer. Hepatogastroenterology 2011, 58(105):239-245.
• [12]Mihmanli M, Dilege E, Demir U: The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology 2004, 51(59):1544-1547.
• [13]Wobbes T, Thomas CM, Segers MF: Evaluation of seven tumor markers (CA 50, CA 19–9, CA 19–9 TruQuant, CA 72–4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer 1992, 69(8):2036-2041.